

Exploring the Current and Future Role of PARP Inhibition in the Management of Prostate Cancer — Presentations

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Results of the Phase III PROfound trial evaluating olaparib versus physician's choice of enzalutamide or abiraterone acetate for patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene alterations, reported at ESMO 2019, included improvement with olaparib in which of the following endpoints?**
 - Radiographic progression-free survival only
 - Overall response rate only
 - Radiographic progression-free survival and overall response rate**
- In the Phase II TRITON2 trial evaluating rucaparib in patients with mCRPC and homologous recombination repair gene deficiency, the highest response rate was reported for which group of patients?**
 - Patients with CDK12 mutations
 - Patients with ATM mutations
 - Patients with BRCA1/2 mutations**
- The Phase II GALAHAD study is evaluating niraparib for which patients with DNA repair gene defects?**
 - Patients with CRPC in the first line of therapy
 - Patients with CRPC who experienced disease progression on taxane-based and androgen receptor-targeted therapy**
 - Patients with castration-sensitive prostate cancer (PC) who experienced disease progression on androgen receptor-targeted therapy
- The ongoing Phase III PROpel trial is investigating the addition of olaparib to abiraterone as first-line therapy for which patients with mCRPC?**
 - Those who have not previously received therapy for mCRPC but may have received anti-androgen therapy for metastatic hormone-sensitive PC
 - Those who have previously received docetaxel for mCRPC
 - Those who have not previously received therapy for mCRPC but may have received docetaxel for metastatic hormone-sensitive PC**
- The combination of talazoparib and enzalutamide is being investigated in the ongoing TALAPRO-2 trial using which dose of talazoparib?**
 - 0.5 mg**
 - 1 mg
 - 2 mg
- In the interim analysis of the TALAPRO-1 trial investigating talazoparib as monotherapy for patients with mCRPC, presented by de Bono and colleagues at the 2020 Genitourinary Cancers Symposium, a composite response was reported in which groups of patients with DNA repair gene mutations?**
 - Patients with BRCA1/2 mutations only
 - Patients with BRCA1/2 and PALB2 mutations only
 - Patients with BRCA1/2, ATM and PALB2 mutations**
- According to research by Marshall and colleagues, patients with localized PC and which Gleason Grade Group have the highest incidence of DNA repair gene mutations?**
 - Group 1
 - Group 2
 - Group 3**
- According to data reported by Schweizer and colleagues, approximately what proportion of patients with ductal adenocarcinoma of the prostate have DNA repair gene mutations?**
 - 10%
 - 20%
 - 50%**

POST-TEST

Exploring the Current and Future Role of PARP Inhibition in the Management of Prostate Cancer — Presentations

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Which of the following PARP inhibitors has demonstrated the strongest PARP1 inhibition and the best PARP trapping activity?
- a. Olaparib
 - b. Talazoparib
 - c. Rucaparib
10. According to recent research by Antonarakis and colleagues, patients with PC with CDK12 mutations are most likely to respond to which of the following therapies?
- a. Chemotherapy
 - b. PARP inhibitors
 - c. PD-1 inhibitors